Bioavailability and Bioequivalence Studies


Bioavailability means the rate and extent to which the active drug substance or therapeutic moiety is absorbed from a pharmaceutical form and becomes available at the site of action. For drugs intended to exhibit a systemic therapeutic effect, bioavailability can be more simply understood as the rate and extent to which a substance or its therapeutic moiety is delivered from a pharmaceutical form into the general circulation. Bioequivalence focus on the release of a drug substance from a drug product and subsequent absorption into systemic circulation. Bioequivalence studies are a surrogate marker for clinical effectiveness and safety data as it would not normally be practical to repeat clinical studies for generic products.


    Related Conference of Bioavailability and Bioequivalence Studies

    January 29-30, 2026

    19th World Drug Delivery Summit

    Paris, France
    February 10-11, 2026

    40th World Congress on Pharmacology and Therapeutics

    Barcelona, Spain
    February 23-24, 2026

    3rd World Congress on Biologics and Biosimilars

    London, UK
    March 23-24, 2026

    36th Annual European Pharma Congress

    London, UK
    March 24-25, 2026

    11th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    April 16-17, 2026

    19th European Biosimilars Congress

    Rome, Italy
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands
    May 28-29, 2026

    3rd International Conference on Pharmacognosy

    Madrid, Spain
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France

    Bioavailability and Bioequivalence Studies Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in